natgillin/translations-raw huggingface dataset:
Nelarabine and ara-G are extensively distributed throughout the body based on combined Phase I pharmacokinetic data at nelarabine doses of 104 to 2,900 mg/m2.
Na osnovi kombiniranih farmakokinetičnih podatkov iz študij I. faze z odmerki nelarabina od 104 do 2.900 mg/m2 je porazdelitev nelarabina in ara-G v telesu obsežna.
Nelarabine has not been studied in individuals with renal impairment.
Pri bolnikih z okvaro jeter uporabe nelarabina niso proučevali.
Nelarabine is a pro-drug of the deoxyguanosine analogue ara-G.
Nelarabin je predzdravilo analoga deoksigvanozina ara-G.
Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T- ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
Nelarabin je indiciran za zdravljenje bolnikov z akutno limfoblastno levkemijo celic T (T-ALL) in limfoblastnim limfomom celic T (T-LBL), pri katerih se bolezen na predhodno zdravljenje z vsaj dvema režimoma kemoterapije ni odzvala ali pa se je ponovila.
Nelarabine is rapidly demethylated by adenosine deaminase (ADA) to ara-G and then phosphorylated intracellularly by deoxyguanosine kinase and deoxycytidine kinase to its 5’-monophosphate metabolite.
Nelarabin se z adenozin-deaminazo (ADA) hitro demetilira v ara-G, v celici pa se nato z deoksigvanozin-kinazo in deoksicitidin-kinazo fosforilira v 5’-monofosfatni presnovek.
Nelarabine must not be diluted prior to administration.
Nelarabina pred uporabo ne smete razredčiti.
Nelfinavir 1250 mg bid (saquinavir/ritonavir 1000/100 mg bid)
nelfinavir 1250 mg dvakrat na dan (sakvinavir/ritonavir 1000/100 mg dvakrat na dan)
Nelfinavir AUC ↑ 152 %
AUC nelfinavirja ↑ 152
Nelfinavir AUC ↑ 152 %
študiji)
Nelfinavir AUC ↑ 20%
AUC nelfinavirja ↑ 20
Nelfinavir AUC ↑ 30%
AUC nelfinavirja ↑ 30
Nelfinavir AUC ↑ 39 %
AUC nelfinavirja ↑ 152
Nelfinavir AUC ↑ 39 %
AUC nelfinavirja ↑ 39
Nelfinavir AUC ↑ 83%
AUC nelfinavirja ↑ 83
Nelfinavir AUC ↑35%
AUC nelfinavirja ↑ 35
Nelfinavir AUC ↑35%
AUC rifabutina ↑ 207
Nelfinavir AUC ↓ 20 %
AUC nelfinavirja ↓ 20
Nelfinavir AUC ↓ 23 %
AUC nelfinavirja ↓ 23
Nelfinavir AUC ↓ 23 %
AUC rifabutina ↑ 83 % AUC nelfinavirja ↓ 23
Nelfinavir AUC ↓ 32 %
AUC nelfinavir ↓ 32
Nelfinavir AUC ↓36%
AUC nelfinavirja ↓ 36
Nelfinavir AUC ↓82%
AUC nelfinavirja ↑ 107
Nelfinavir AUC ↓82%
AUC nelfinavirja ↓ 82
Nelfinavir Cmax ↓37%
Cmax nelfinavirja ↓ 37
Nelfinavir concentrations not
Koncentracija nelfinavirja ni bila merjena.
Nelfinavir increases terfenadine plasma concentrations.
Nelfinavir poveča plazemske koncentracije terfenadina.
Nelfinavir levels may increase on stopping St. John’s wort, and the dose of nelfinavir may need adjusting.
Po prekinitvi jemanja šentjanževke lahko pride do porasta koncentracij nelfinavirja in zato bo morda treba prilagoditi odmerek nelfinavirja.
Nelfinavir reversibly binds to the active site of HIV protease and prevents cleavage of the polyproteins resulting in the formation of immature non-infectious viral particles.
Nelfinavir se reverzibilno veže na aktivno mesto HIV- proteaze in prepreči cepitev polibeljakovin, kar povzroči nastanek nezrelih neinfektivnih virusnih delcev.
Nelfinavir/Dolutegravir
fosamprenavir
Nelfinavir/Efavirenz
lopinavirju/ritonavirju
Nelfinavir/efavirenz (750 mg q8h/600 mg once daily)
(750 mg q8h/600 mg enkrat na dan)
Nelfinavir: the AUC, Cmin and Cmax of nelfinavir were increased by 15 %, 14 %, and 12 %, respectively, when given with amprenavir.
Nelfinavir: Ob sočasnem dajanju z amprenavirjem so se AUC, Cmin in Cmax nelfinavirja zvečale, in sicer AUC za 15 %, Cmin za 14 % in Cmax za 12 %.
NELSame criteria as for CHR but ANC >1x109/l and platelets >20x109/l
NEL enaki kriteriji kot za CHR, a ANC  1 x 109/l in trombociti  20 x 109/l
NELSame criteria as for CHR but ANC >1x109/l and platelets >20x109/l
obolelosti zunaj kostnega mozga
Nematodes
Nematodi
Nemdatine 10 mg film-coated tablets (tablets) are white, capsule-shaped, biconvex, 9.8 mm x 4.9 mm in size, with score line and the marking “M 10” engraved on the scored side
Nemdatine 10 mg filmsko obložene tablet so bele, v obliki kapsule, bikonveksne, velikosti 9,8 mm x 4,9 mm z razdelilno zarezo in vtisnjeno oznako “M10” na zarezani strani.
Nemdatine 10 mg tablets memantine hydrochloride
Nemdatine 10 mg tablete memantinijev klorid
Nemdatine 15 mg tablets memantine hydrochloride
Nemdatine 15 mg tablete memantinijev klorid
Nemdatine 20 mg film-coated tablets (tablets) are dark pink, oval shaped, biconvex, 12.6 mm x 7 mm in size, with the marking “M20” engraved on one side.
Nemdatine 20 mg filmsko obložene tablete so temno rožnate, ovalne, bikonveksne, velikosti 12,6 mm x 7 mm, z vtisnjeno oznako “M20” na eni strani.
Nemdatine 20 mg tablets memantine hydrochloride
Nemdatine 20 mg tablete memantinijev klorid
Nemdatine 5 mg film-coated tablets Nemdatine 10 mg film-coated tablets Nemdatine 15 mg film-coated tablets Nemdatine 20 mg film-coated tablets Memantine hydrochloride
Nemdatine 5 mg filmsko obložene tablete Nemdatine 10 mg filmsko obložene tablete Nemdatine 15 mg filmsko obložene tablete Nemdatine 20 mg filmsko obložene tablete memantinijev klorid
Nemdatine 5 mg tablets memantine hydrochloride
Nemdatine 5 mg tablete memantinijev klorid
Nemdatine acts on these NMDA-receptors improving the transmission of nerve signals and the memory.
Nemdatine deluje na receptorje NMDA in izboljša prenos živčnih signalov in spomin.
Nemdatine belongs to a group of medicines called NMDA- receptor antagonists.
Nemdatine spada v skupino zdravil, ki se imenujejo antagonisti receptorjev NMDA.
Nemdatine belongs to a group of medicines known as anti-dementia medicines.
Nemdatine sodi v skupino zdravil, znanih kot zdravila za zdravljenje demence.
Nemdatine is a medicine used to treat patients with moderate to severe Alzheimer’s disease, a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour.
Nemdatine je zdravilo, ki se uporablja za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo, vrsto demence (možganske bolezni), ki postopoma prizadene spomin, intelektualno sposobnost in vedenje.
Nemdatine is a ‘generic medicine’.
Zdravilo Nemdatine je „generično zdravilo“.
Nemdatine is not recommended for children and adolescents under the age of 18 years.
Zdravila Nemdatine ne priporočajo otrokom in mladostnikom, mlajšim od 18 let.
Nemdatine is used for the treatment of patients with moderate to severe Alzheimer’s disease.
Zdravilo Nemdatine uporabljamo za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
Nemdatine should be administered once a day and should be taken at the same time every day.
Zdravilo Nemdatine je treba dajati enkrat dnevno in ob istem času vsak dan.
Neo-vaccinations given during treatment with Raptiva may induce antibody levels lower than those observed in non-treated subjects, but the clinical significance of this is unknown.
Bolniki, ki so imeli novo cepljenje med zdravljenjem z Raptivo, so razvili manj protiteles kot tisti, ki niso uporabljali Raptive, vendar kliničen pomen tega pojava ni znan.
Neoadjuvant Treatment of Breast Cancer
Neoadjuvantno zdravljenje raka dojk
Neoclarityn 5 mg film-coated tablets are packed in blisters in packs of 1, 2, 3, 5, 7, 10, 14, 15, 20, 21,
5 mg filmsko obložene tablete Neoclarityn so na voljo v pretisnih omotih po 1, 2, 3, 5, 7, 10, 14, 15,
Neoclarityn 5 mg film-coated tablets desloratadine
Neoclarityn 5 mg filmsko obložena tableta desloratadin
Neoclarityn 5 mg orodispersible tablet
Neoclarityn 5 mg orodisperzibilna tableta
Neoclarityn 5 mg orodispersible tablets
Neoclarityn 5 mg orodisperzibilne tablete
Neoclarityn contains desloratadine which is an antihistamine.
Zdravilo Neoclarityn vsebuje desloratadin, ki je antihistaminik.
Neoclarityn is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:
Zdravilo Neoclarityn je indicirano pri odraslih in mladostnikih, starih 12 let in več, za lajšanje simptomov:
Neoclarityn is indicated in adults, adolescents aged 12 years and older and children aged 6 – 11 years old for the relief of symptoms associated with:
Zdravilo Neoclarityn je indicirano pri odraslih, mladostnikih, starih 12 let in več, in otrocih, starih 6 – 11 let, za lajšanje simptomov:
Neoclarityn is indicated in adults, adolescents and children over the age of 1 year for the relief of symptoms associated with:
Zdravilo Neoclarityn je indicirano pri odraslih, mladostnikih in otrocih, starejših od 1 leta, za lajšanje simptomov:
Neoclarityn may be taken with or without a meal.
Zdravilo Neoclarityn se lahko jemlje s hrano ali brez nje.
Neoclarityn oral solution contains sorbitol
Zdravilo Neoclarityn peroralna raztopina vsebuje sorbitol
Neoclarityn oral solution contains sorbitol.
Neoclarityn peroralna raztopina vsebuje sorbitol.
Neoclarityn oral solution is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy).
Zdravilo Neoclarityn peroralna raztopina se uporablja tudi za lajšanje simptomov urtikarije (težave s kožo zaradi alergije).
Neoclarityn oral solution is available in bottles of 30, 50, 60, 100, 120, 150, 225 and 300 ml, with a childproof cap.
Neoclarityn peroralna raztopina je na voljo v stekleničkah po 30, 50, 60, 100, 120, 150, 225 in 300 ml, z zaporko, varno za otroke.
Neoclarityn oral solution with food, drink and alcohol
Zdravilo Neoclarityn peroralna raztopina skupaj s hrano, pijačo in alkoholom
Neoclarityn orodispersible tablet contains aspartame
Zdravilo Neoclarityn orodisperzibilna tableta vsebuje aspartam
Neoclarityn orodispersible tablet does not need to be taken with water or liquid.
Zdravila Neoclarityn orodisperzibilna tableta vam ni treba jemati z vodo ali tekočino.
Neoclarityn orodispersible tablet is packed in unit dose blisters in packs of
Neoclarityn orodisperzibilne tablete so na voljo v pretisnih omotih po
Neoclarityn orodispersible tablet with food, drink and alcohol
Zdravilo Neoclarityn orodisperzibilna tableta skupaj s hrano, pijačo in alkoholom
Neoclarityn tablets effectively controlled symptoms for 24 hours.
Zdravilo Neoclarityn učinkovito obvladuje te simptome za čas 24 ur.
Neoclarityn tablets were effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire.
Zdravilo Neoclarityn je učinkovito ublažilo težave, povezane s sezonskim alergijskim rinitisom, kar je pokazal skupni rezultat vprašalnika o kakovosti življenja bolnikov z rinitisom in konjunktivitisom.
Neoclarityn was effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire.
Zdravilo Neoclarityn je učinkovito ublažilo težave, povezane s sezonskim alergijskim rinitisom, kar so pokazali skupni rezultati vprašalnika o kakovosti življenja bolnikov z rinitisom in konjunktivitisom.
Neocolipor is administered to female pigs – both sows and gilts - in order to immunise their offspring against neonatal enterotoxicosis.
Zdravilo Neocolipor se daje svinjam in mladicam za imunizacijo zaroda pred poporodno enterotoksemijo.
Neofordex 40 mg tablet dexamethasone
Neofordex 40 mg tablete deksametazon
Neofordex contains lactose
Zdravilo Neofordex vsebuje laktozo.
Neofordex has moderate influence on the ability to drive and use machines.
Zdravilo Neofordex ima zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
Neofordex is a medicine that contains the active substance dexamethasone.
Neofordex je zdravilo, ki vsebuje zdravilno učinkovino deksametazon.
Neofordex is available as 40 mg tablets.
Zdravilo Neofordex je na voljo v obliki tablet po 40 mg.
Neofordex is used to treat adult patients with multiple myeloma, a cancer of the blood affecting the white blood cells that produce antibodies.
Zdravilo Neofordex se uporablja za zdravljenje odraslih bolnikov z multiplim mielomom, t.j. krvnim rakom, ki prizadene bele krvne celice, ki proizvajajo protitelesa.
Neomycin Phenol red
neomicin fenol rdeče
neonatal (see section 4.6)
indrom odtegnitve zdravila pri novorojenčku (glejte poglavje 4.6)
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1,800 mg/kg/day (x 6 – 17 the MRHD on a mg/m2 basis).
V študijah pri novorojenčkih in mladičih živali so dokazali, da pri podganah in psih, pri odmerkih do 1800 mg/kg/dan (6-kratna do 17-kratna vrednost največjega priporočenega odmerka pri ljudeh glede na mg/m2) ni bilo neželenih učinkov na običajna obdobja razvoja in dozorevanja.
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1,800 mg/kg/day (x 6-17 the MRHD on a mg/m2 basis)
V študijah pri novorojenčkih in mladičih živali so dokazali, da pri podganah in psih, pri odmerkih do 1.800 mg/kg/dan (6-kratna do 17-kratna vrednost največjega priporočenega odmerka pri ljudeh glede na mg/m2) ni bilo neželenih učinkov na običajna obdobja razvoja in dozorevanja)
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6 – 17 the MRHD on a mg/m2 basis).
V študijah pri novoskotenih živalih in mladičih živali so dokazali, da pri podganah in psih pri odmerkih do 1800 mg/kg/dan (6-kratna do 17-kratna vrednost največjega priporočenega odmerka pri ljudeh glede na mg/m2) ni bilo neželenih učinkov na standardne parametre razvoja in dozorevanja.
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6 – 17 the MRHD on a mg/m2 basis).
V študijah pri novoskotenih živalih in mladičih živali so dokazali, da pri podganah in psih, pri odmerkih do 1800 mg/kg/dan (6-kratna do 17-kratna vrednost največjega priporočenega odmerka pri ljudeh glede na mg/m2), ni bilo neželenih učinkov na standardne parametre razvoja in dozorevanja.
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6- 17 the MRHD on a mg/m2 basis)
V študijah pri novoskotenih živalih in mladičih živali so dokazali, da pri podganah in psih pri odmerkih do 1800 mg/kg/dan (6-kratna do 17-kratna vrednost največjega priporočenega odmerka pri ljudeh glede na mg/m2) ni bilo neželenih učinkov na standardne parametre razvoja in dozorevanja.
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6-17 the MRHD on a mg/m2 basis)
V študijah pri novoskotenih živalih in mladičih živali so dokazali, da pri podganah in psih pri odmerkih do 1800 mg/kg/dan (6-kratna do 17-kratna vrednost največjega priporočenega odmerka pri ljudeh glede na mg/m2) ni bilo neželenih učinkov na standardne parametre razvoja in dozorevanja.
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6-17 the MRHD on a mg/m2 basis)
V študijah pri novoskotenih živalih in mladičih živali so dokazali, da pri podganah in psih pri odmerkih do 1800 mg/kg/dan (6-kratna do 17-kratna vrednost največjega priporočenega odmerka pri ljudeh glede na mg/m2), ni bilo neželenih učinkov na standardne parametre razvoja in dozorevanja.
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6-17 the MRHD on a mg/m2 basis)
V študijah pri novoskotenih živalih in mladičih živali so dokazali, da pri podganah in psih, pri odmerkih do 1800 mg/kg/dan (6-kratna do 17-kratna vrednost največjega priporočenega odmerka pri ljudeh glede na mg/m2) ni bilo neželenih učinkov na običajna obdobja standardne parametre razvoja in dozorevanja.
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6-17 the MRHD on a mg/m2 basis)
V študijah pri novoskotenih živalih in mladičih živali so dokazali, da pri podganah in psih, pri odmerkih do 1800 mg/kg/dan (6-kratna do 17-kratna vrednost največjega priporočenega odmerka pri ljudeh glede na mg/m2) ni bilo neželenih učinkov na standardne parametre razvoja in dozorevanja.
Neonatal calves less than 12 hours of age.
Novorojena teleta v starosti manj kot 12 ur.
Neonatal growth was reduced in rats while exposed to Victoza, and persisted in the post­weaning period in the high dose group.
Pri podganah se je med izpostavljenostjo zdravilu Victoza upočasnila neonatalna rast, to pa se je v skupini, ki je prejemala velik odmerek, nadaljevalo tudi v obdobju po prenehanju sesanja.
Neonatal piglets derive passive immunity via ingestion of colostrum from vaccinated sows/gilts.
Novorojeni pujski pridobijo pasivno imunost s kolostrumom cepljenih svinj ali mladic.
Neonatal piglets derive passive immunity via ingestion of colostrum from vaccinated sows/gilts.
Potomci cepljenih svinj in mladic pridobijo pasivno imunost s kolostrumom.
Neonatal-Onset Multisystem Inflammatory Disease (NOMID), also called Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA),
multisistemsko vnetno bolezen z začetkom pri novorojenčku (NOMID), imenovano tudi kronični vnetni nevrološki, kožni in sklepni sindrom (CINCA)
Neonates and infants are known to have diminished MetHb reductase activity compared to adults.
Znano je, da je aktivnost methemoglobin-reduktaze pri novorojenčkih in dojenčkih manjša kot pri odraslih.
Neonates and infants under the age of 2 years (see section 4.4)
Novorojenčki in dojenčki, mlajši od 2 let (glejte poglavje 4.4).
Neoplams
Novotvorbe
Neoplasm
Novotvorbe
neoplasm (tumour) progression new cancers of the bone marrow or blood, such as acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS)
napredovanje novotvorb (tumorjev), nova rakava obolenja kostnega mozga ali krvi, kot sta akutna mieloidna levkemija (AML) ali mielodisplastični sindrom (MDS),
Neoplasm benign, malignant and unspecified (incl. cysts and polyps)
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
Neoplasm malignant, Leukaemia plasmacytic, Renal cell carcinoma, Mass, Mycosis fungoides, Neoplasm benign*
maligne neoplazme, plazmocitna levkemija, karcinom ledvičnih celic, masa, fungoidna mikoza, benigne neoplazme
Neoplasm progression
napredovanje neoplazme
Neoplasm with increased bleeding risk
novotvorba s povečanim tveganjem krvavitve,
neoplasm with increased bleeding risk
tumor s povečanim tveganjem za krvavitev,
Neoplasms
Neoplazme
Neoplasms
Novotvorbe
Neoplasms benign and
Benigne, maligne in
Neoplasms benign and malignant
Benigne in maligne neoplazme
Neoplasms benign and malignant (incl cysts and polyps)
Benigne in maligne
Neoplasms benign and malignant (including
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
Neoplasms benign and malignant disorders: Liver tumour
Benigne in maligne novotvorbe: jetrni tumor.
Neoplasms benign and malignant:
Benigne in maligne neoplazme:
Neoplasms benign,
Benigne, maligne in
Neoplasms benign,
makularni edem2
Neoplasms benign, malignant and unspecified
Benigne in maligne neoplazme (vključno s cistami in polipi)
Neoplasms benign, malignant and unspecified
Benigne, maligne in neopredeljene neoplazme (vključno s cistami in polipi)
Neoplasms benign, malignant and unspecified
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benigne in maligne neoplazme ( vključno s cistami in polipi)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benigne in maligne neoplazme (vključno s cistami in polipi):
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benigne in maligne novotvorbe (vključno s cistami in polipi)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benigne maligne in neopredeljene neoplazme (vključno s cistami in polipi)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
Neoplasms benign, malignant and unspecified (incl. cysts and polyps)
Benigne in maligne neoplazme (vključno s cistami in polipi)
Neoplasms benign, malignant and unspecified (incl. cysts and polyps)
Benigne, maligne in neopredeljene neoplazme (vključno s cistami in polipi)
Neoplasms benign, malignant and unspecified (incl. cysts and polyps)
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
Neoplasms benign, malignant and unspecified (incl. cysts and polyps): Uncommon: Non-melanoma skin cancers* (see section 4.4) Rare: Lymphoma, melanoma (see section 4.4)
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi): Občasni: nemelanomski kožni rak* (glejte poglavje 4.4) Redki: limfom, melanom (glejte poglavje 4.4)
Neoplasms benign, malignant and unspecified (includes cysts and polyps)
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
Neoplasms benign, malignant and unspecified (including cysts and polyps)
(vključno s cistami in polipi)
Neoplasms benign, malignant and unspecified (including cysts and polyps)
Benigne, maligne in neopredel- jene novotvorbe (vključno s cistami in polipi)
Neoplasms benign, malignant and unspecified (including cysts and polyps)
Benigne, maligne in neopredelje ne novotvorbe (vključno s cistami in polipi)
Neoplasms benign, malignant and unspecified (including cysts and polyps)
novotvorbe (vključno s cistami in polipi)
Neoplasms benign, malignant and unspecified (including cysts and polyps)*
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in
Neoplasms benign, malignant and unspecified (including cysts and polyps):
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi):
Neoplasms benign, malignant and unspecified (inl. cysts and polyps)
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
Neoplasms benign, malignant andunspecified(incl cysts and polyps)
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
Neoplasms benign, malignant, and unspecified
Benigne, maligne in neopredeljene novotvorbe
Neoplasms including lymphoproliferative disorders, skin cancers (melanomas and non- melanomas), sarcomas (Kaposi's and non-Kaposi's) and uterine cervical cancer in situ (see section 4.4).
Novotvorbe, vključno z limfoproliferativnimi boleznimi, kožnim rakom (melanomskim in nemelanomskim), sarkomom (Kaposijevim in ne- Kaposijevim) in rakom materničnega vratu in situ (glejte poglavje 4.4)
Neoplasms, benign, malignant and unspecified
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
Neoplasms, benign, malignant and unspecified (incl cysts and polyps)*
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
Neoplasms, benign, malignant and unspecified (incl. cysts and polyps)
Benigne, maligne in neopredeljene neoplazme (vključno s cistami in polipi)
NeoRecormon 10,000 IU
NeoRecormon 10.000 i.e.
NeoRecormon 10,000 IU injection IV/SC use
NeoRecormon 10.000 i.e. injekcija i.v./s.c. uporaba.
NeoRecormon 10,000 IU solution for injection in pre-filled syringe
NeoRecormon 10.000 i.e. raztopina za injiciranje v napolnjeni injekcijski brizgi
NeoRecormon 10,000 IU solution for injection in pre-filled syringe Epoetin beta
NeoRecormon 10.000 i.e. raztopina za injiciranje v napolnjeni injekcijski brizgi epoetin beta
neorecormon 10.000 IU
neorecormon 10.000 i.e.
NeoRecormon 20,000 IU injection IV/SC use
NeoRecormon 20.000 i.e. injekcija i.v./s.c. uporaba